Antibody Therapeutics Conference 2017: Oncology, Immunology, and Infectious Diseases
Greetings! Taiwan Antibody Association “Antibody Therapeutics Conference 2017: Oncology, Immunology, and Infectious Diseases” will be held on November 3rd, 2017 at Academia Sinica in Taiwan. The first annual ATC forum was held in 2013. Since then, during these years, application of antibody therapeutics has been successful and has progressed vigorously across the world. In TAA, we aim to effectively coordinate among the industrial, governmental, academic, and research institutions to develop advanced emerging technologies for effective discovery, production and translation in antibody therapeutics.
This year, the meeting covers a broad spectrum of topics on the new advances, including treatment of cancers, immune-mediated and infectious diseases. This meeting aims to provide scientists an opportunity to face-to-face discuss the comprehensive scientific knowledge and experiences on how to develop a therapeutic antibody from discovery, development to commercialization.
We sincerely thank each of your for attending and supporting our meeting and bringing your expertise to our gathering. We wish you a pleasant experience in Taiwan and the ATC 2017.
Friday November 3rd, 2017
Venue: 2F the First Conference Room, the Center of Academic Activities, Academia Sinica
點我前往活動網站
活動網站連結
Scientific Program
Friday |
Topic |
Speaker |
---|---|---|
0830 - 0900 |
Registration |
|
0900 - 0910 |
Opening Remarks |
|
Kenote |
||
Moderator |
Academician Andrew H.-J. Wang |
|
0910 - 0955 |
Keynote speech: Tissue-based biomarker measurements in immune-oncology: where are we at and where we are heading |
Dr. Angelo De Marzo |
Session I: Perspectives on Current Trends & Future Opportunities |
||
Moderator |
Dr. Herbert Wu |
|
1000 - 1035 |
Fill the Gap and Share the Success |
Dr. Qinhua Cindy Ru |
1035 - 1050 |
Coffee break |
|
1050 - 1120 |
Development of Anti-Rabies MAbs for Post-Exposure Prophylaxis |
Dr. Eric Tsao |
Session II: Emerging Targets |
||
Moderator |
Dr. Chien-Tsun Kuan |
|
1125 - 1200 |
Engineering Immune Effector Molecules for the Development of Novel Immunotherapies for Cancer and Autoimmunity |
Dr. Yoram Reiter |
1200 - 1235 |
Therapeutic Antibody Discovery at Genentech |
Dr. Yan Wu |
1235 -1400 |
Lunch (Taiwan Antibody Association Members Meeting and Poster Viewing) |
|
Session III: Technologies for Antibody Discovery, Engineering, and Manufacture |
||
Moderator |
Dr. Chia-Cheng Wu |
|
1405 - 1440 |
Technologies and their role in the evolution of therapeutic antibodies |
Dr. Partha S. Chowdhury |
1440 - 1510 |
XenoComputer: Develop fully humanized antibody drugs by computer-aided human V(D)J recombination |
Dr. Tian-Lu Cheng |
1510 - 1545 |
Developing Targeted Fusion Proteins for the Treatment of Cancer |
Dr. Gregory Adams |
1545 - 1615 |
From TuNEX to LusiNEX, Biologics development in Taiwan |
Dr. Karen Wen |
1615 - 1635 |
Coffee break |
|
Session IV: Translation and Development of Antibody Therapeutics |
||
Moderator |
Academician Alice Yu |
|
1640 - 1715 |
Biomarker Strategy for Therapeutic Antibody In Early Clinical Development |
Dr. Larry Lo |
1715 - 1745 |
Insights from a Success Story of a Local Biotech Leader: Development of Ibalizumab ~the 1st Monoclonal Antibody for HIV Treatment |
Dr. Meng-Hsin Chen |
1745 - 1815 |
PD1/PDL1 checkpoint inhibitor therapy and their roles in the cancer immunotherapy |
Dr. James Chih-Hsin Yang |
1815 - 1820 |
Closing Remarks |